MedGene Therapeutics

About:

MedGene Therapeutics is a biotech company developing ACT treatments for two cancers using NIH patented technology.

Description:

MedGene Therapeutics is focused on developing ACT treatments (PMBC derived tumor-reactive T cells-Natural Unmodified CD8+ lymphocytes) for two cancers—MSTS (metastatic soft tissue sarcoma) and MFTC (metastatic follicular thyroid cancer)—using NIH patented technology with Worldwide Exclusive License Agreement of commercialization.

Total Funding Amount:

$1.15M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Silver Spring, Maryland, United States

Founded Date:

2015-01-01

Founders:

Yong H Park

Number of Employees:

1-10

Last Funding Date:

2021-06-25

IPO Status:

Private

Industries: